Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 4/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903270 | 0.84 | NPC1 (0.40) | S100A4CYP11B1CYP11B2MEN1KMT2A | |
| SCHEMBL21903238 | 0.82 | CYP11B2 (0.42) | S100A4DRD2DRD4CYP11B1CYP11B2 | |
| SCHEMBL29986526 | 0.80 | CYP11B2 (0.39) | CCR5CYP11B1CYP11B2 | |
| SCHEMBL21970098 | 0.80 | CYP11B2 (0.39) | CCR5CYP11B1CYP11B2 | |
| SCHEMBL30372076 | 0.80 | HRH3 (0.51) | CCR5HRH3MEN1KMT2APGR | |
| SCHEMBL21903272 | 0.75 | MAP3K5 (0.39) | HRH3 | |
| SCHEMBL22898412 | 0.74 | NR1H2 (0.40) | HRH3MEN1KMT2A | |
| SCHEMBL21903240 | 0.74 | MDM2 (0.36) | CYP11B1CYP11B2AKR1B1MDM2 | |
| Hydrochloric Acid SCHEMBL29985745 | 0.74 | MAP3K5 (0.39) | HRH3 | |
| SCHEMBL30564277 | 0.73 | HRH3 (0.52) | CCR5HRH3MEN1KMT2APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | S100A4 2264/4885CCR5 1987/4885DRD2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.